- Clinical Trials
Our technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. We are developing our lead product candidate REQORSA to be administered with targeted therapies and with immunotherapies for NSCLC. We continue to conduct preclinical research to explore how REQORSA may be administered with targeted therapies and immunotherapies in other solid tumors, and we are researching how other cancer fighting genes can enhance our portfolio using our ONCOPREX Nanoparticle Delivery System. Recently, we expanded our pipeline to include Small Cell Lung Cancer and expect to commence a clinical trial by year end 2022. Using a different gene therapy delivery system, we are also developing our preclinical diabetes candidate, GPX-002. The following table summarizes our product development pipeline.
Tagrisso® is a registered trademark of AstraZeneca.
Keytruda® is a registered trademark of Merck.
Tarceva® is a registered trademark of Astellas and the Roche Group of companies.